Roche helps further reduce risk of severe illness for transplant patients by expanding the portfolio to include Adenovirus Test on the cobas 6800/8800 Systems

- Immunocompromised transplant recipients are at risk of major complications when infected with adenovirus, a common and highly contagious virus

- Healthcare professionals can use this new test to determine whether transplant patients are at risk of developing severe illness from adenovirus infection

- The Adenovirus Test leverages the flexibility, automation, and reliability of the cobas omni Utility Channel on the cobas 6800/8800 Systems, improving workflow efficiencies compared to laboratory developed tests

PLEASANTON, California, Jan. 15, 2020 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the commercial availability of a quantitative Adenovirus (ADV) Test for use with the cobas omni Utility Channel on the cobas 6800/8800 Systems in countries accepting the CE mark. The new Adenovirus Test will help healthcare professionals better monitor and manage severely immunocompromised transplant patients at risk of infections.

"Transplant patients face the risk of significant complications due to adenovirus and other infections," said Mario Torres, Head of Roche Molecular Diagnostics. "This new addition to our menu provides a more comprehensive solution for laboratories to offer improved monitoring tools so that treatment plans can be adjusted as necessary, providing better patient care."

Roche's comprehensive transplant menu now allows critical transplant testing (Cytomegalovirus, Epstein-Barr virus, BK virus and human Adenovirus) on the consolidated cobas 6800/8800 Systems along with other infectious disease tests. The cobas 6800/8800 Systems offer the fastest time-to-results with the highest throughput and the longest walk-away time available among automated molecular platforms, providing laboratories with improved operating efficiency and the flexibility to adapt to increasing testing demands.

About the quantitative Adenovirus Real Time PCR Test
The Adenovirus Test is based on real-time PCR (polymerase chain reaction) and provides quantitative accuracy for detection and quantification of human adenovirus. The test is designed to work in conjunction with the cobas omni Utility Channel reagent to simplify workflow. The assay calibrators are traceable to the World Health Organization (WHO) international standard for adenovirus and reports in International Units Per Millilitre (IU/mL). The test minimises variability and complexity in testing, offering an alternative to lab-developed tests (LDTs), and reduces workload and alleviates risk for laboratories.